Lilly Intensifies AI Push with Three Major Collaborations in One Month

　　【Pharmaceutical Network Enterprise News】As a key force in disrupting traditional drug research and development models, AI can significantly shorten the drug discovery and preclinical research cycle. This year, in order to build differentiated competitive advantages as soon as possible in an increasingly intense context, many pharmaceutical companies such as Eli Lilly, Roche, Novartis, Genentech, and Gilead have been heavily investing in the AI-driven drug development sector.
 

Since 2025, among many companies, Eli Lilly's investment in AI has undoubtedly been substantial and frequent. Within the past month alone, it has successively reached collaborations with multiple partners, including NVIDIA and Insilico Medicine.
 

On October 28, Eli Lilly announced a collaboration with NVIDIA to jointly build a "supercomputer" for the pharmaceutical industry. This system will drive the "AI factory" to comprehensively manage the entire AI lifecycle, from data ingestion, model training, fine-tuning to high-volume inference. It aims to test potential drug molecules more efficiently and expand the boundaries and depth of drug discovery.
 

On November 5, Eli Lilly and Ailux Biologics, a subsidiary of XtalPi, reached a strategic collaboration with a potential total value of up to $345 million. Eli Lilly will leverage Ailux's proprietary AI antibody discovery platform to accelerate the discovery of bispecific antibodies (BsAbs) across multiple therapeutic areas and empower its internal pipeline development.
 

On November 8, Eli Lilly announced a global R&D collaboration and licensing agreement worth up to $1.2 billion with SANEGENEBIO to jointly develop and commercialize RNAi therapies for metabolic diseases. The two parties will promote the development of RNAi drug candidates targeting metabolic diseases based on SANEGENEBIO's proprietary LEAD platform. The LEAD platform is a tissue-selective delivery technology independently developed by SANEGENEBIO, capable of achieving efficient and specific delivery of RNAi drugs in extrahepatic tissues and cells.
 

On November 10, Eli Lilly and Insilico Medicine reached a strategic collaboration for drug discovery. According to the agreement, Insilico Medicine will leverage its extensively validated Pharma.AI platform and specialized expertise in drug discovery to generate, design, and optimize candidate compounds for innovative targets agreed upon by both parties. Insilico Medicine is entitled to receive up to $100 million in total from this collaboration, including an upfront payment, research and development milestone payments, and tiered royalties on net sales following the future commercialization of the drug.
 

Notably, this month Eli Lilly announced the official launch of its open innovation platform — the Shanghai Innovation Incubator (Lilly Gateway Labs, LGL). This is the second innovation incubator that Eli Lilly has established in China, following Beijing. The innovation platform can accommodate 8 to 10 high-potential biotechnology companies and approximately 100 scientific research talents, providing top-tier laboratory space and connecting to Eli Lilly's global network of scientists and professional resources. This will help startup teams accelerate the development of transformative drugs while maintaining their independence.
 

Currently, Eli Lilly has deeply integrated AI into the core of drug innovation. By 2025, significant innovative achievements have already been made, with products like Orforglipron nearing market launch and 17 AI-designed drugs advancing in clinical trials, greatly improving R&D efficiency… In the future, through infrastructure development, strategic partner ecosystems, and full-chain R&D penetration, Eli Lilly will continue to strengthen its leading position in the AI pharmaceuticals field.
 

　　Disclaimer: In no case shall the information or opinions expressed in this article constitute investment advice to any person.